Search

Your search keyword '"Wallerand, Hervé"' showing total 128 results
Start Over Author "Wallerand, Hervé"
128 results on '"Wallerand, Hervé"'

1. Accuracy of FDG-PET/CT for Response Evaluation of Muscle-Invasive Bladder Cancer following Neoadjuvant or Induction Chemotherapy

Author

Fitoussi, Olivier, primary, Roche, Jean Baptiste, additional, Riviere, Julien, additional, Wallerand, Hervé, additional, Poulain, Jean Eude, additional, Gordien, Pierre, additional, Galland, Sigolène, additional, Henriques, Bénédicte, additional, Dupin, Camille, additional, Vincent, Muriel, additional, Kuratle, Thomas, additional, Saffarini, Mo, additional, and Ramos-Pascual, Sonia, additional

Published
2023
Full Text
View/download PDF

13. Inhibidores de la tirosin-quinasa en el tratamiento del cáncer de vejiga músculo-infiltrante y el cáncer de próstata hormono-refractario

Author

Wallerand, Hervé, Robert, Grégoire, Bernhard, Jean-Christophe, Ravaud, Alain, and Patard, Jean-Jacques

Subjects
Cáncer de próstata, Prostate cancer, Cáncer de próstata hormono refractario, Inhibidor de la tirosin-quinasa, Bladder cancer, Tyrosine kinase inhibitor, Adjuvant therapy, Terapia adyuvante, Inhibidor de la proteín-quinasa, Cáncer de vejiga, Protein kinase inhibitor, Hormone refractory prostate cancer, Muscle invasive bladder cancer, Cáncer de vejiga músculo infilrante
Abstract

Objetivo: Se sabe que varias proteín-quinasas son activadas en las células tumorales e impulsan el crecimiento y progresión tumoral. En el carcinoma de células renales metastásico, los inhibidores de la tirosin-quinasa (TKIs) han logrado importantes beneficios en progresión libre de enfermedad y supervivencia global. Los TKIs pueden ser también considerados como una prometedora opción de tratamiento en tumores vesicales y prostáticos. Nuestro objetivo fue dar a conocer los artículos más relevantes publicados para confirmar el interés de la utilización de los TKI en el tratamiento de estos tumores. Métodos: Se realizó una busqueda sistemática en PubMed y se revisaron los artículos recuperados. Las palabras clave utilizadas fueron: inhibidor de la tirosin-quinasa, inhibidor de la protein-quinasa, cáncer de próstata hormono-refractario, cáncer de vejiga músculo-infiltrante. Las publicaciones más relevantes de ciencia básica y ensayos clínicos controlados y aleatorizados fueron resumidas y analizadas. Resultados: En cuanto al cáncer de vejiga, el tratamiento TKI es una de las estrategias terapéuticas más estudiadas en el campo de la terapia dirigida. De hecho, se ha sugerido que dirigiendo solamente TK y/o asociándola con quimioterapia citotóxica puede representar una opción prometedora para tratar el cáncer de vejiga localmente avanzado y/o metastásico. En cuanto al cáncer de próstata hormono-refractario (CPHR), los datos recogidos son aún confusos. Los estudios de ciencia básica encontraron una interesante expresión de receptores EGF y VEGF en las células tumorales confirmando la idea de que los TKI podrían resultar eficientes en el CPHR. Sin embargo la mayoría de estudios publicados de fase II encontraron un débil efecto sobre los síntomas y la calidad de vida sin ninguna disminución en los niveles de PSA o en la supervivencia general. Conclusión: Los TKIs todavía no han alcanzado en tumores vesicales o prostátivos una eficacia similar a lo que se ha obtenido en el carcinoma renal metastásico. Se necesitan más estudios para establecer el papel de ese enfoque en tumores no renales. Objectives: Various protein kinases are known to be activated in cancer cells and drive tumor growth and progression. In metastatic renal cell carcinoma tyrosine-kinase inhibitors (TKIs) have achieved significant progression-free and overall survival improvements. For bladder and prostate cancers TKIs may also be considered as a promising treatment option. Our aim was to report the most relevant published articles to support the interest of the use of TKIs in the treatment of bladder and prostate cancer. Method: PubMed database and bibliographies of retrieved articles were reviewed. The key words used were tyrosine-kinase inhibitor, protein-kinase inhibitor, hormone refractory prostate cancer, muscle invasive bladder cancer. The most relevant publications from basic science and clinical randomized controlled studies were summarized and analyzed. Results: Regarding bladder cancer, TKI treatment is one of the most studied therapeutic strategies in the field of targeted therapy. Indeed, it has been suggested that targeting TK alone and/or in association with cytotoxic chemotherapy may represent a promising option for treating locally advanced and/or metastatic bladder cancer. Concerning hormone refractory prostate cancer (HRPC), collected data are still confusing. Basic science studies found an interesting expression of EGF and VEGF receptors on cancer cells supporting the idea that TKIs could be efficient in HRPC. Nonetheless most of published clinical phase II studies found a weak effect on symptoms and quality of life without any decrease in PSA levels or overall survival. Conclusion: TKIs have not yet achieved in bladder and prostate cancers similar efficacy to what has been obtained in metastatic renal cell carcinoma. Further studies are needed to establish the place of such an approach in non renal tumors.

Published
2010

14. [Conservative management of Corynebacterium urealyticum encrusted cystitis]

Author

Khallouk , Abdelhak, Wallerand , Hervé, Kleinclauss , François, Bittard , Hugues, Bernardini , Stéphane, Service d'urologie, andrologie et transplantation rénale, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Service de Néphrologie et Urologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC ( HOTE GREFFON ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Université de Franche-Comté ( UFC ), Saas, Philippe, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC)

Subjects
Male, MESH: Aged, MESH: Humans, [SDV.IMM] Life Sciences [q-bio]/Immunology, Corynebacterium Infections, MESH : Male, MESH : Humans, MESH : Aged, MESH : Corynebacterium Infections, urologic and male genital diseases, MESH: Male, MESH: Cystitis, MESH: Corynebacterium Infections, Cystitis, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, Humans, [SDV.IMM]Life Sciences [q-bio]/Immunology, MESH : Cystitis, Aged
Abstract

International audience; The authors report the case of a 75-year-old patient who developed Corynebacterium urealyticum encrusted cystitis six months after open prostatectomy, complicated by vesicocutaneous fistula, which required bladder catheterization for several days. Encrustation of the bladder wall induced marked bilateral ureteropyelocaliceal dilatation without renal failure. Medical treatment by antibiotic therapy and oral acidification of the urine allowed regression of the plaques and resolution of the dilatation.

Published
2006

15. [Simultaneous embolization of a large arteriovenous fistula and a renal pseudoaneurysm]

Author

Khallouk , Abdelhak, El-Ammari , Jalal Eddine, Wallerand , Hervé, Kleinclauss , François, Bittard , Hugues, Bernardini , Stéphane, Service d'urologie, andrologie et transplantation rénale, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Saas, Philippe, Service de Néphrologie et Urologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC ( HOTE GREFFON ), and Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Université de Franche-Comté ( UFC )

Subjects
Adult, [SDV.IMM] Life Sciences [q-bio]/Immunology, MESH : Aneurysm, False, MESH: Renal Artery, Renal Veins, Renal Artery, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, Humans, MESH : Female, MESH : Embolization, Therapeutic, MESH: Aneurysm, False, MESH: Humans, MESH : Humans, MESH: Adult, MESH : Adult, MESH : Renal Veins, Embolization, Therapeutic, MESH : Arteriovenous Fistula, MESH: Embolization, Therapeutic, MESH: Renal Veins, Arteriovenous Fistula, MESH : Renal Artery, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, MESH: Arteriovenous Fistula, MESH: Female, Aneurysm, False
Abstract

International audience; The authors report the cases of a 41-year-old woman with a large arteriovenous fistula between a branch of the renal artery and the main renal vein in the renal hilum and a peripheral pseudoaneurysm secondary to a knife wound to the kidney. These lesions were successfully treated by embolization. In the light of this case, the authors illustrate the possibility of performing more than one embolization on the same kidney and emphasize the successful embolization of a large, high-flow arteriovenous fistula.

Published
2006

16. [Atypical cysts and risk of renal cancer: value and danger of the Bosniak classification]

Author

Loock , Pierre-Yves, Debiere , François, Wallerand , Hervé, Bittard , Hugues, Kleinclauss , François, Service de Néphrologie et Urologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC ( HOTE GREFFON ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Université de Franche-Comté ( UFC ), Service d'urologie, andrologie et transplantation rénale, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Saas, Philippe, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC)

Subjects
Adult, Male, MESH: Kidney Diseases, Cystic, [SDV.IMM] Life Sciences [q-bio]/Immunology, MESH : Retrospective Studies, MESH : Male, MESH : Aged, MESH: Aged, 80 and over, Risk Factors, MESH: Risk Factors, Humans, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, MESH : Female, MESH : Middle Aged, MESH : Aged, 80 and over, Aged, Retrospective Studies, Aged, 80 and over, MESH: Aged, MESH : Kidney Diseases, Cystic, MESH: Humans, MESH: Middle Aged, MESH : Humans, MESH: Adult, MESH: Retrospective Studies, Kidney Diseases, Cystic, Middle Aged, MESH : Adult, MESH : Risk Factors, Kidney Neoplasms, MESH: Male, MESH : Kidney Neoplasms, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, MESH: Kidney Neoplasms, MESH: Female
Abstract

International audience; OBJECTIVE: The objective of this study was to devaluate the risk of renal cancer in patients with atypical renal cysts and to compare radiological data used to establish the Bosniak classification with clinical or histological data. MATERIAL AND METHOD: We performed a retrospective study on 37 patients managed in our establishment for atypical renal cyst between January 1995 and April 2003. The following criteria were analysed: gender, age, clinical examination and circumstances of discovery imaging findings, Bosniak classification, treatment modalities and follow-up data. These criteria were compared in two populations according to the presence or absence of associated renal cancer. RESULTS: In this series, 6 patients presented a stage II cyst. No cancer was demonstrated in this group of cysts. Ten patients presented a stage IIF cyst and 2 cancers were detected in this group (i.e. 20%). Fourteen patients presented a stage III cyst, with a cancer in 4 cases (30%) and 7 patients presented a stage IV cyst with 6 cancers (86%). CONCLUSION: The Bosniak classification is currently the reference classification fr the diagnosis of cystic diseases of the kidney. Although stages I and II (cysts with minor changes not requiring surveillance) and stages III and IV (suspicious malignant cysts which require surgical exploration) raise few diagnostic problems, stage IIF (indeterminate cyst requiring radiological surveillance) may be the source of diagnostic difficulties with a risk of missing an associated renal cancer.

Published
2006

17. [Urologic cancer in patients with kidney transplantation]

Author

Guichard , Guillaume, Wallerand , Hervé, Bittard , Hugues, Chalopin , Jean-Marc, Kleinclauss , François, Service de Néphrologie et Urologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Service d'urologie, andrologie et transplantation rénale, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC ( HOTE GREFFON ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Université de Franche-Comté ( UFC ), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Saas, Philippe, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC)

Subjects
Male, MESH: Humans, [SDV.IMM] Life Sciences [q-bio]/Immunology, MESH : Male, MESH : Humans, Prostatic Neoplasms, Kidney Transplantation, Kidney Neoplasms, MESH: Male, MESH : Kidney Neoplasms, MESH: Kidney Transplantation, MESH: Urinary Bladder Neoplasms, Urinary Bladder Neoplasms, MESH : Urinary Bladder Neoplasms, MESH: Prostatic Neoplasms, Humans, [SDV.IMM]Life Sciences [q-bio]/Immunology, MESH : Kidney Transplantation, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, MESH: Kidney Neoplasms, MESH : Prostatic Neoplasms, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2006

18. Renal Cell Carcinoma (RCC) in Patients With End-Stage Renal Disease Exhibits Many Favourable Clinical, Pathologic, and Outcome Features Compared With RCC in the General Population

Author

Neuzillet, Yann, primary, Tillou, Xavier, additional, Mathieu, Romain, additional, Long, Jean-Alexandre, additional, Gigante, Marc, additional, Paparel, Philippe, additional, Poissonnier, Laura, additional, Baumert, Hervé, additional, Escudier, Bernard, additional, Lang, Hervé, additional, Rioux-Leclercq, Nathalie, additional, Bigot, Pierre, additional, Bernhard, Jean-Christophe, additional, Albiges, Laurence, additional, Bastien, Laurence, additional, Petit, Jacques, additional, Saint, Fabien, additional, Bruyere, Franck, additional, Boutin, Jean-Michel, additional, Brichart, Nicolas, additional, Karam, Georges, additional, Branchereau, Julien, additional, Ferriere, Jean-Marie, additional, Wallerand, Hervé, additional, Barbet, Sébastien, additional, Elkentaoui, Hicham, additional, Hubert, Jacques, additional, Feuillu, Benoit, additional, Theveniaud, Pierre-Etienne, additional, Villers, Arnauld, additional, Zini, Laurent, additional, Descazeaux, Aurélien, additional, Roupret, Morgan, additional, Barrou, Benoit, additional, Fehri, Karim, additional, Lebret, Thierry, additional, Tostain, Jacques, additional, Terrier, Jean-Etienne, additional, Terrier, Nicolas, additional, Martin, Lucille, additional, Dugardin, Fabrice, additional, Galliot, Ismaël, additional, Staerman, Frédéric, additional, Azemar, Marie-Dominique, additional, Irani, Jacques, additional, Tisserand, Baptiste, additional, Timsit, Marc-Olivier, additional, Sallusto, Federico, additional, Rischmann, Pascal, additional, Guy, Laurent, additional, Valeri, Antoine, additional, Deruelle, Charles, additional, Azzouzi, Abdel-Rahmène, additional, Chautard, Denis, additional, Mejean, Arnaud, additional, Salomon, Laurent, additional, Rigaud, Jérôme, additional, Pfister, Christian, additional, Soulié, Michel, additional, Kleinclauss, François, additional, Badet, Lionel, additional, and Patard, Jean-Jacques, additional

Published
2011
Full Text
View/download PDF

19. 1411 ONCOLOGIC OUTCOMES AND EVOLUTION IN PATIENTS WITH PT0 DISEASE FOLLOWING RADICAL CYSTECTOMY FOR BLADDER CANCER. A MULTICENTRIC STUDY

Author

Drouin, Sarah J., primary, Roupret, Morgan, additional, Neuzillet, Yann, additional, Rigaud, Jerome, additional, Hitier, Mariam, additional, Xylinas, Evanguelos, additional, Iborra, François, additional, Cornu, Jean-Nicolas, additional, Champetier, Denis, additional, Botto, Henry, additional, Rozet, François, additional, Flamand, Vincent, additional, Bastide, Cyrille, additional, Salomon, Laurent, additional, Cormier, Luc, additional, Durand, Xavier, additional, Lunardi, Pierre, additional, Nouhaud, François-Xavier, additional, Mazerolles, Catherine, additional, Bitker, Marc-Olivier, additional, Rischmann, Pascal, additional, Patard, Jean-Jacques, additional, Ferlicot, Sophie, additional, Wallerand, Hervé, additional, Casenave, Julien, additional, paule, Aurelie, additional, Bensalalh, Karim, additional, Gres, Pascal, additional, Peyronnet, Benoit, additional, Droupy, Stephane, additional, Poissonnier, Laura, additional, Irani, Jacques, additional, Soulie, Michel, additional, and Pfister, Christian, additional

Published
2011
Full Text
View/download PDF

22. Salvage Radiotherapy After High-Intensity Focussed Ultrasound for Recurrent Localised Prostate Cancer

Author

Riviere, Julien, primary, Bernhard, Jean-Christophe, additional, Robert, Grégoire, additional, Wallerand, Hervé, additional, Deti, Edouard, additional, Maurice-Tison, Sylvie, additional, Ardiet, Jean-Michel, additional, Maire, Jean-Philippe, additional, Richaud, Pierre, additional, Ferriere, Jean-Marie, additional, Ballanger, Philippe, additional, Gelet, Albert, additional, and Pasticier, Gilles, additional

Published
2010
Full Text
View/download PDF

24. Predictive Factors for Ipsilateral Recurrence After Nephron-sparing Surgery in Renal Cell Carcinoma

Author

Bernhard, Jean-Christophe, primary, Pantuck, Allan J., additional, Wallerand, Hervé, additional, Crepel, Maxime, additional, Ferrière, Jean-Marie, additional, Bellec, Laurent, additional, Maurice-Tison, Sylvie, additional, Robert, Grégoire, additional, Albouy, Baptiste, additional, Pasticier, Gilles, additional, Soulie, Michel, additional, Lopes, David, additional, Lacroix, Bertrand, additional, Bensalah, Karim, additional, Pfister, Christian, additional, Thuret, Rodolphe, additional, Tostain, Jacques, additional, De La Taille, Alexandre, additional, Salomon, Laurent, additional, Abbou, Clément, additional, Colombel, Marc, additional, Belldegrun, Arie S., additional, and Patard, Jean-Jacques, additional

Published
2010
Full Text
View/download PDF

25. 211 LEVEL OF EXPRESSION AND PROGNOSTIC VALUE OF CXCL4, CXCL4L1 AND CXCR3B IN CLEAR CELL RENAL CELL CARCINOMA

Author

Bernhard, Jean-Christophe, primary, Soulet, Fabienne, additional, Quemener, Cathy, additional, Deminiere, Colette, additional, Fergelot, Patricia, additional, Sire, Marie, additional, Pineau, Raphaël, additional, Wallerand, Hervé, additional, Pasticier, Gilles, additional, Merlio, Jean-Philippe, additional, Ballanger, Philippe, additional, Ravaud, Alain, additional, Ferriere, Jean-Marie, additional, and Bikfalvi, Andreas, additional

Published
2010
Full Text
View/download PDF

26. 2064 RENAL CELL CARCINOMAS ARISING IN NATIVE KIDNEYS OF DIALYZED AND TRANSPLANT PATIENTS: ARE THEY DIFFERENT ENTITIES?

Author

Neuzillet, Yann, primary, Badet, Lionel, additional, Gigante, Marc, additional, Salomon, Laurent, additional, Bastien, Laurence, additional, Petit, Jacques, additional, Saint, Fabien, additional, Tillou, Xavier, additional, Rioux-Leclercq, Nathalie, additional, Mathieu, Romain, additional, Bruyere, Franck, additional, Boutin, Jean-Michel, additional, Brichart, Nicolas, additional, Rigaud, Jérôme, additional, Karam, Georges, additional, Branchereau, Julien, additional, Ferriere, Jean-Marie, additional, Wallerand, Hervé, additional, Barbet, Sebastien, additional, Elkentaoui, Hicham, additional, Hubert, Jacques, additional, Feuillu, Benoit, additional, Theveniaud, Pierre-Etienne, additional, Villers, Arnauld, additional, Zini, Laurent, additional, Descazeaux, Aurélien, additional, Roupret, Morgan, additional, Barrou, Benoit, additional, Fehri, Karim, additional, Lebret, Thierry, additional, Tostain, Jacques, additional, Terrier, Jean-Etienne, additional, Paparel, Philippe, additional, Poissonnier, Laura, additional, Long, Jean-Alexandre, additional, Terrier, Nicolas, additional, Kleinclauss, François, additional, Martin, Lucille, additional, Pfister, Christian, additional, Dugardin, Fabrice, additional, Galliot, Ismaël, additional, Staerman, Frédéric, additional, Azemar, Marie-Dominique, additional, Irani, Jacques, additional, Tisserand, Baptiste, additional, Mejean, Arnaud, additional, Timsit, Marc-Olivier, additional, Soulie, Michel, additional, Sallusto, Fédérico, additional, Rischmann, Pascal, additional, Guy, Laurent, additional, Valeri, Antoine, additional, Deruelle, Charles, additional, Azzouzi, Abdel-Rahmène, additional, Chautard, Denis, additional, Bigot, Pierre, additional, Escudier, Bernard, additional, Correas, Jean-Michel, additional, Lang, Hervé, additional, Baumert, Hervé, additional, and Patard, Jean-Jacques, additional

Published
2010
Full Text
View/download PDF

27. 505 CLINICO-PATHOLOGICAL AND OUTCOME FEATURES OF RENAL CELL CARCINOMAS IN PATIENTS WITH END STAGE RENAL DISEASE

Author

Neuzillet, Yann, primary, Salomon, Laurent, additional, Bastien, Laurence, additional, Petit, Jacques, additional, Saint, Fabien, additional, Tillou, Xavier, additional, Rioux-Leclercq, Nathalie, additional, Mathieu, Romain, additional, Bruyere, Franck, additional, Boutin, Jean-Michel, additional, Brichart, Nicolas, additional, Rigaud, Jérôme, additional, Karam, Georges, additional, Branchereau, Julien, additional, Ferriere, Jean-Marie, additional, Wallerand, Hervé, additional, Barbet, Sébastien, additional, Elkentaoui, Hicham, additional, Hubert, Jacques, additional, Feuillu, Benoit, additional, Theveniaud, Pierre-Etienne, additional, Villers, Arnauld, additional, Zini, Laurent, additional, Descazeaux, Aurélien, additional, Roupret, Morgan, additional, Barrou, Benoit, additional, Fehri, Karim, additional, Lebret, Thierry, additional, Tostain, Jacques, additional, Terrier, Jean-Etienne, additional, Paparel, Philippe, additional, Badet, Lionel, additional, Poissonnier, Laura, additional, Long, Jean-Alexandre, additional, Terrier, Nicolas, additional, Kleinclauss, François, additional, Martin, Lucille, additional, Pfister, Christian, additional, Dugardin, Fabrice, additional, Galliot, Ismaël, additional, Staerman, Frédéric, additional, Azemar, Marie-Dominique, additional, Irani, Jacques, additional, Tisserand, Baptiste, additional, Mejean, Arnaud, additional, Timsit, Marc-Olivier, additional, Soulie, Michel, additional, Sallusto, Federico, additional, Rischmann, Pascal, additional, Guy, Laurent, additional, Valeri, Antoine, additional, Deruelle, Charles, additional, Gigante, Marc, additional, Azzouzi, Abdel-Rahmène, additional, Chautard, Denis, additional, Bigot, Pierre, additional, Escudier, Bernard, additional, Correas, Jean-Michel, additional, Lang, Hervé, additional, Baumert, Hervé, additional, and Patard, Jean-Jacques, additional

Published
2010
Full Text
View/download PDF

28. Reply

Author

Wallerand, Hervé, primary, Ballanger, Philippe, additional, Ferrière, Jean-Marie, additional, and Ravaud, Alain, additional

Published
2010
Full Text
View/download PDF

32. VEGF EXPRESSION AS BIOMARKER OF SUNITINIB CLINICAL RESPONSE IN METASTATIC RENAL CLEAR CELL CARCINOMA

Author

Bastien, Laurence, primary, Paule, Bernard, additional, Maille, Pascale, additional, Azoulay, Sandy, additional, Allory, Yves, additional, Patard, Jean-Jacques, additional, Rioux-Leclercq, Nathalie, additional, Crepel, Maxime, additional, Wallerand, Hervé, additional, Bernhard, Jean-Christophe, additional, Game, Xavier, additional, Mazerolles, Catherine, additional, Guillotreau, Julien, additional, Ruffion, Alain, additional, Decaussin-Petrucci, Myriam, additional, Zini, Laurent, additional, Leroy, Xavier, additional, Berton, Nicolas, additional, Culine, Stéphane, additional, Salomon, Laurent, additional, Hoznek, Andras, additional, Vordos, Dimitri, additional, Abbou, Claude C, additional, and de la Taille, Alexandre, additional

Published
2009
Full Text
View/download PDF

35. Gefitinib Inhibits the Growth and Invasion of Urothelial Carcinoma Cell Lines in which Akt and MAPK Activation Is Dependent on Constitutive Epidermal Growth Factor Receptor Activation

Author

Nicolle, Gaëlle, primary, Daher, Ahmad, additional, Maillé, Pascale, additional, Vermey, Marcel, additional, Loric, Sylvain, additional, Bakkar, Ashraf, additional, Wallerand, Hervé, additional, Vordos, Dimitrios, additional, Vacherot, Francis, additional, de Medina, Sixtina Gil Diez, additional, Abbou, Claude C., additional, Kwast, Theodore Van der, additional, Thiery, Jean-Paul, additional, Radvanyi, François, additional, and Chopin, Dominique K., additional

Published
2006
Full Text
View/download PDF

37. Sensitive Allele-Specific PCR Assay Able to Detect FGFR3 Mutations in Tumors and Urine from Patients with Urothelial Cell Carcinoma of the Bladder

Author

Bakkar, Ashraf A, primary, Quach, Viviane, primary, Le Borgne, Anaïg, primary, Toublanc, Marianne, primary, Henin, Dominique, primary, Wallerand, Hervé, primary, Radvanyi, François, primary, Bittard, Hugues, primary, Ravery, Vincent, primary, Gibod, Laurent Boccon, primary, de Medina, Sixtina Gil Diez, primary, Chopin, Dominique K, primary, and Grandchamp, Bernard, primary

Published
2005
Full Text
View/download PDF

40. 250: Bladder Cancers in Current Smokers Present Higher Stage and Grade at Initial Diagnosis, Result of a Case Control Study

Author

Dominique, Chopin K., primary, Iwatsubo, Yuriko, additional, Bakkar, Ashraf, additional, Vordos, Dimitrios, additional, Wallerand, Hervé, additional, Ravery, Vincent V., additional, Gibbod, Laurent Boccon, additional, Fontaine, Eric, additional, Beurton, Danile, additional, Billebaud, Thierry, additional, Jaurand, Marie Claude, additional, Abbou, Clément-Claude, additional, de Medina, Sixtina Gil Diez, additional, and Pairon, Jean Claude, additional

Published
2004
Full Text
View/download PDF

43. Towards a Modern and More Capable French Army.

Author

Wallerand, Hervé

Subjects
*SPECIAL operations (Military science), *MILITARY helicopters, *WAR, *MILITARY science, *ARMED Forces
Abstract

The article provides an overview of the various aspects of the overall ongoing process for the modernisation and re-equipment of the French Land Forces. It highlights the TF Dragon, the task force built up by the 2nd French Foreign Legion Infantry Regiment for the operations in Afghanistan. It also mentions the deterrent and reassurance contribution of the Tiger attack helicopter. The new equipment deployed in Afghanistan gave an ability to take advantage of the basic principles of waging war.

Published
2010

44. PREDICTIVE FACTORS FOR LOCAL RECURRENCE AFTER NEPHRON SPARING SURGERY IN RENAL CELL CARCINOMA

Author

Bernhard, Jean-Christophe, Ferriere, Jean-Marie, Pantuck, Allan J, Crepel, Maxime, Wallerand, Herve, Bellec, Laurent, Robert, Gregoire, Lam, John S, Soulie, Michel, Albouy, Baptiste, Pasticier, Gilles, Lopes, David, Lacroix, Bertrand, Bensalah, Karim, Pfister, Christian, Guille, Francois, Tostain, Jacques, de la Taille, Alexandre, Salomon, Laurent, Abbou, Clement-Claude C, Colombel, Marc, Belldegrun, Arie S, and Patard, Jean- Jacques

Published
2008
Full Text
View/download PDF

47. Oncologic outcomes and survival in pT0 tumors after radical cystectomy in patients without neoadjuvant chemotherapy: results from a large multicentre collaborative study.

Author

Rouprêt M, Drouin SJ, Larré S, Neuzillet Y, Botto H, Hitier M, Rigaud J, Crew J, Xylinas E, Salomon L, Cornu JN, Iborra F, Champetier D, Rozet F, Flamand V, Bastide C, Cormier L, Durand X, Lunardi P, Rischmann P, Nouhaud FX, Ferlicot S, Patard JJ, Floch AP, Irani J, Peyronnet B, Bensalah K, Poissonnier L, Grès P, Droupy S, Casenave J, Wallerand H, Soulié M, and Pfister C

Subjects
Adult, Aged, Aged, 80 and over, Carcinoma, Transitional Cell pathology, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Recurrence, Local mortality, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local surgery, Neoplasm Staging, Prognosis, Retrospective Studies, Survival Rate, Urinary Bladder Neoplasms pathology, Carcinoma, Transitional Cell mortality, Carcinoma, Transitional Cell surgery, Cystectomy mortality, Urinary Bladder Neoplasms mortality, Urinary Bladder Neoplasms surgery
Abstract

Purpose: To assess the postsurgical survival of patients with urothelial carcinoma of the bladder with pT0 tumor at pathologic examination of cystectomy specimens., Methods: A multi-institutional, retrospective database was analyzed with data from 4758 radical cystectomy (RC) patients who underwent RC without neoadjuvant chemotherapy and who were diagnosed with pT0 on the basis of the pathologic specimen. Survival curves were estimated. A multivariate Cox model was used to evaluate the association between prognosis factors and disease recurrence or survival., Results: Overall, 258 patients (5.4%) were included in the study. The median age was 64 years. At last resection, 171 tumors were invasive (at least pT2), and 87 were not. Median follow-up was 51 months. At multivariate analysis, initial location of the tumor and absence of lymphadenectomy were associated with tumor recurrence (P = 0.03 and P = 0.005, respectively) and specific mortality (P = 0.005 and 0.001, respectively). The main limitation of the study is its retrospective design, which is due to the rarity of this situation. Cancer-specific and recurrence-free survival rates were 89 and 85%, respectively, at 5 years and 82 and 80%, respectively, at 10 years., Conclusions: Despite acceptable oncological outcomes, patients with a pT0 tumor at the time of RC are still at risk of recurrence and progression and should not be considered to be entirely cured. In this population, stringent follow-up according to current recommendations should be effective.

Published
2011
Full Text
View/download PDF

48. Tyrosine-kinase inhibitors in the treatment of muscle invasive bladder cancer and hormone refractory prostate cancer.

Author

Wallerand H, Robert G, Bernhard JC, Ravaud A, and Patard JJ

Subjects
ErbB Receptors antagonists & inhibitors, ErbB Receptors physiology, Hormone Antagonists therapeutic use, Humans, Male, Muscle, Smooth, Neoplasm Invasiveness, Protein-Tyrosine Kinases physiology, Receptors, Vascular Endothelial Growth Factor antagonists & inhibitors, Receptors, Vascular Endothelial Growth Factor physiology, Signal Transduction, Treatment Failure, Prostatic Neoplasms drug therapy, Protein-Tyrosine Kinases antagonists & inhibitors, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms pathology
Abstract

Objectives: Various protein kinases are known to be activated in cancer cells and drive tumor growth and progression. In metastatic renal cell carcinoma tyrosine-kinase inhibitors (TKIs) have achieved significant progression-free and overall survival improvements. For bladder and prostate cancers TKIs may also be considered as a promising treatment option. Our aim was to report the most relevant published articles to support the interest of the use of TKIs in the treatment of bladder and prostate cancer., Method: PubMed database and bibliographies of retrieved articles were reviewed. The key words used were tyrosine-kinase inhibitor, protein-kinase inhibitor, hormone refractory prostate cancer, muscle invasive bladder cancer. The most relevant publications from basic science and clinical randomized controlled studies were summarized and analyzed., Results: Regarding bladder cancer, TKI treatment is one of the most studied therapeutic strategies in the field of targeted therapy. Indeed, it has been suggested that targeting TK alone and/or in association with cytotoxic chemotherapy may represent a promising option for treating locally advanced and/or metastatic bladder cancer. Concerning hormone refractory prostate cancer (HRPC), collected data are still confusing. Basic science studies found an interesting expression of EGF and VEGF receptors on cancer cells supporting the idea that TKIs could be efficient in HRPC. Nonetheless most of published clinical phase II studies found a weak effect on symptoms and quality of life without any decrease in PSA levels or overall survival., Conclusion: TKIs have not yet achieved in bladder and prostate cancers similar efficacy to what has been obtained in metastatic renal cell carcinoma. Further studies are needed to establish the place of such an approach in non renal tumors.

Published
2010

49. Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma.

Author

Robert G, Gabbay G, Bram R, Wallerand H, Deminière C, Cornelis F, Bernhard JC, Ravaud A, and Ballanger P

Subjects
Aged, Biopsy, Needle, Carcinoma, Renal Cell surgery, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Immunohistochemistry, Kidney Neoplasms surgery, Magnetic Resonance Imaging, Neoplasm Staging, Nephrectomy methods, Protein Kinase Inhibitors therapeutic use, Sunitinib, Treatment Outcome, Carcinoma, Renal Cell drug therapy, Carcinoma, Renal Cell pathology, Indoles therapeutic use, Kidney Neoplasms drug therapy, Kidney Neoplasms pathology, Neoadjuvant Therapy, Pyrroles therapeutic use
Abstract

The authors present the first case report of complete histologic remission after neoadjuvant sunitinib treatment on primary renal tumour and vena cava thrombus. A 78-yr-old woman with an Eastern Cooperative Oncology Group (ECOG) score of 0 presented with a T3b renal tumour. She refused surgical treatment but agreed to percutaneous biopsy and medical treatment. A Fuhrman III renal cell carcinoma was histologically confirmed on percutaneous biopsy, and sunitinib treatment was administered over 6 mo. A significant objective response was observed for tumour size and thrombus. The patient finally accepted surgical treatment. Pathologic examination concluded with a complete response of primary tumour and thrombus.

Published
2009
Full Text
View/download PDF

50. [Anti-angiogenic treatment in the management of metastatic renal cell carcinoma].

Author

Sire M, Wallerand H, Kilkoski F, Grenier N, Ferrière JM, and Ravaud A

Subjects
Angiogenesis Inhibitors adverse effects, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Humanized, Benzenesulfonates adverse effects, Bevacizumab, Brain Neoplasms secondary, Carcinoma, Renal Cell blood supply, Carcinoma, Renal Cell secondary, Drug Administration Schedule, Female, Humans, Indoles adverse effects, Kidney Neoplasms blood supply, Male, Middle Aged, Niacinamide analogs & derivatives, Phenylurea Compounds, Pyridines adverse effects, Pyrroles adverse effects, Retrospective Studies, Sorafenib, Sunitinib, Angiogenesis Inhibitors therapeutic use, Antibodies, Monoclonal therapeutic use, Benzenesulfonates therapeutic use, Carcinoma, Renal Cell drug therapy, Indoles therapeutic use, Kidney Neoplasms drug therapy, Pyridines therapeutic use, Pyrroles therapeutic use
Abstract

Anti-angiogenic treatments have recently been incorporated as a milestone in the management of metastatic renal cell carcinoma. This retrospective study explores this new practice in 94 patients treated by sorafenib, bevacizumab or sunitinib in the department of oncology of CHU of Bordeaux in a 32 months period. The adverse effects reported are similar than those from prospective trials but for some different in frequency or severity. Efficacy of these drugs appeared more modest than expected from phase III trials. An objective response rate or stabilisation longer than six month was seen in 35% of the patients. Median overall survival was 14.1 months (IC 95%: 8.3-18.7 months). Nevertheless, the population considered in this study had a worse prognosis with more patients with an altered general status (OMS 2 or 3: 13.8%).

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results